Clinical Trial

Patients With Primary Biliary Cholangitis(PBC)

Study acronym: GLYPP
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Primary Biliary Cholangitis (PBC) is a chronic autoimmune cholestatic liver disease characterized by the progressive destruction of small intrahepatic bile ducts, leading to chronic cholestasis, hepatic fibrosis, and, in advanced stages, cirrhosis. Recent advances in the understanding of PBC pathophysiology have highlighted the central role of immune, inflammatory, and metabolic alterations in disease onset and progression.
Trial Details
NCT Number NCT07629128
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Primary Biliary Cholangitis, Liver Fibrosis, Cirrhosis, Liver, Blood Sugar; High
Enrollment 30 participants
Start Date 2026-05-18
Primary Completion 2027-05 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-05